A

Allakos

D
ALLK
USD
-0.06
(-4.2553%)
Market Closed
19,617.00
Volume
-1.74
EPS
-
Div Yield
-0.574468
P/E
119,948,462.55
Market Cap
Today
-4.2553%
1 Week
7.143%
1 Month
94.384%
6 Months
9.756%
12 Months
-34.625%
Year To Date
-50.459%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALLO
-0.015
(-0.4666%)
USD
A
ALKS
-0.32
(-1.0925%)
USD
A
ALLO
-0.015
(-0.4666%)
USD

Title:
Allakos

Sector:
Healthcare
Industry:
Biotechnology
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Do you need help or have a question?
Contact Us